An Open-Label, Two-Period, Randomized, Crossover Study to Assess the Relative Bioavailability of GSK1120212 Tablet Formulation and the GSK1120212 Pediatric Oral Solution Formulation Following Single-Dose Administration to Adult Subjects With Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 16 Nov 2017
At a glance
- Drugs Trametinib (Primary)
- Indications Solid tumours
- Focus Pharmacokinetics
- Sponsors GlaxoSmithKline
- 01 Nov 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 31 Aug 2012 Planned End Date changed from 1 Aug 2012 to 1 Sep 2012 as reported by ClinicalTrials.gov.
- 03 Aug 2012 Status changed from recruiting to not yet recruiting as reported by ClinicalTrials.gov.